Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05428735 · ClinicalTrials.gov registry record · NA
The DRAGON 2 Trial
A NA study of Colorectal Cancer Liver Metastases (CRLM) and Small Future Liver Remnant (FLR), sponsored by Maastricht University.
- Recruiting
- Registry status
- NA
- Development phase
- 348
- Enrollment target
- 20
- Study locations
NCT05428735: Recruiting NA study of Colorectal Cancer Liver Metastases (CRLM) and Small Future Liver Remnant (FLR), sponsored by Maastricht University.
NCT05428735 is a NA study of Colorectal Cancer Liver Metastases (CRLM) and Small Future Liver Remnant (FLR) that is actively recruiting participants, run by Maastricht University. The registered enrollment target is 348 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05428735, a NA study of Colorectal Cancer Liver Metastases (CRLM) and Small Future Liver Remnant (FLR), is actively recruiting participants, sponsored by Maastricht University.
- RECRUITING
- Registry status
- NA
- Development phase
- 348 participants
- Enrollment target
- 20
- Study locations
Study Summary
In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).
Primary Outcome
Volume sufficient for resection will be based on the first week or third week CT/MR Volumetry. Vauthey calculation for TLV will be used and the FLR volume will be measured centrally (objective panel)
Conditions Studied
Interventions
- PROCEDURE Embolization
Study Locations (20)
Other
- McGill University Health Center - Montreal
- IRCCS San Raffaele Hospital - Milan
- Amphia - Breda
- Maxima Medisch Centrum - Eindhoven
- Universitair Medisch Centrum Utrecht - Utrecht
Ontario
- Juravinski Hospital and Cancer Centre - Hamilton
- The Ottawa Hospital - Ottawa
- Sunnybrook Hospital - Toronto
Connecticut
- Yale New Haven Hospital - New Haven
Victoria
- Monash Medical Centre - Clayton
Vienna
- Social Medical Center, South - Vienna
Brussels Capital
- Hôpital Erasme - Brussels
Liège
- CHU de Liège - Liège
Namen
- CHU-UCL Namur site Godinne - Yvoir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 348 participants |
| Start Date | 2022-04-01 |
| Est. Completion | 2029-06-30 |
| Phase | NA |
What NCT05428735 shows while recruiting
NCT05428735 is an interventional study that assigns participants to a tested intervention. The registered 348 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (75% lower).
The record links to 2 conditions, with Colorectal Cancer Liver Metastases (CRLM) appearing as the primary indexed condition, and to 1 intervention - of which Embolization is the first listed.
NCT05428735 names 20 study sites across 14 states, led by Other, Ontario, Connecticut.
Frequently Asked Questions
What is clinical trial NCT05428735 about?
NCT05428735 is a clinical study titled "The DRAGON 2 Trial". In the randomized controlled DRAGON 2 trial study subjects will be randomized between two arms, PVE alone (control group) and PVE/HVE (interventional group).
What is the current status of trial NCT05428735?
This trial is currently recruiting. It is a NA study. The enrollment target is 348 participants. The study started on 2022-04-01. Estimated completion is 2029-06-30.
What conditions does trial NCT05428735 study?
This clinical trial studies the following conditions: Colorectal Cancer Liver Metastases (CRLM), Small Future Liver Remnant (FLR).
What interventions are being tested in trial NCT05428735?
The interventions under investigation include: Embolization (PROCEDURE).
Who is sponsoring clinical trial NCT05428735?
This trial is sponsored by Maastricht University, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05428735 being conducted?
This trial has 20 study locations across Connecticut, Victoria, Vienna, Brussels Capital, Liège. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer Liver Metastases (CRLM)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05428735's enrollment target sits among peer trials
348 302nd of 2000 higher than 1,699 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04041479 · 348 participants · Phase 3
Biomarker-guided rTMS for Treatment Resistant Depression
- NCT04530565 · 348 participants · Phase 3
Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults
- NCT05787379 · 348 participants · NA
Care for Veterans Post-COVID-19
- NCT05815784 · 348 participants · Phase 2
Myopia Control: a Comparison Study Between Atropine and MiSight
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI